[1]
|
Gunzler, V.A., Steffens, G.J., Otting, F., et al. (1982) Structural relationship between human high and low molecular mass urokinase. Hoppe-Seyler’s Zeitschrift für physiologische Chemie, 363, 133-141.
doi:10.1515/bchm2.1982.363.1.133
|
[2]
|
Husain, S.S., Gurewich, V. and Liinsik, B. (1983) Purification and partial characterization of a single-chain high-molecular-weight form of urokinase. Archives of Biochemistry and Biophysics, 220, 31-38.
doi:10.1016/0003-9861(83)90383-1
|
[3]
|
Wan, T.C., Sssowski, L., Reich, E., (1982) A proenzyme form of human urokinase. Journal of Biological Chemistry, 257, 7262-7268.
|
[4]
|
Toki, N. and Sumi, H. (1982) Urinary trypsin inhibitor and urokinase activities in renal diseases. Acta Haematol, 45, 119-128.
|
[5]
|
Wun, T.C., Schlenning, W.D. and Reich, E. (1982) Isolation and characterization of urokinase from human plasma. Journal of Biological Chemistry, 257, 32763283.
|
[6]
|
Homes, W.E., Pennica, D., Blaber, M., Rey, M.W., Guenzler, W.M., Staffen, G.J. and Heyneker, H.L. (1985) Cloning and expression of the gene for prourokinase in Escherichia coli. Biotechnology, 3, 923-929.
doi:10.1038/nbt1085-923
|
[7]
|
Nelles, L., Lijnen, H.R., Collen, D. and Holmes, W.E., (1987) Characterization of recombinant human single chain urokinase-type plasminogen activator mutants. Journal of Biological Chemistry, 262, 5682-5689.
|
[8]
|
Cheng, S.M., Lee, S.G. and Kalyan, N.K. (1988) Isolation of a human cDNA of urokinase and its expression in COS-1 cells. Gene, 679, 357-363.
doi:10.1016/0378-1119(88)90447-7
|
[9]
|
Scarborough, R., Rose, J.W., Hsu, M.A., Phillips, D.R., Fried, V.A., Campbell, A.M., Nannizzi, L. and Charo, I.F. (1991) Barbourin. A GPIIb/IIIa-specific integrin antagonist from the venom of Sistrurus m barbouri. Journal of Biological Chemistry, 566, 9359-9362.
|
[10]
|
Minoux, H., Chipot, C., Brown, D. and Maigret, B. (2000) Structural analysis of the KGD sequence loop of barbourin an alphaIIbbeta3-specific disintegrin. Journal of Computer-Aided Molecular Design, 14, 317-327.
doi:10.1023/A:1008182011731
|
[11]
|
Plow, E.F., Marguerie, G. and Ginsberg, M. (1987) Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactions. Biochemical Pharmacology, 36, 4036-4040. doi:10.1016/0006-2952(87)90558-2
|
[12]
|
Maeda, S. (1989) Gene transfer vectors of a baculovirus, Bombyx mori unclear polyhedrosis virus, and their use for expression of foregn genes in insect cells [C]. In: Mitsuhashi, J., Ed., Invertebrate Cell System Appliactions, CRC Press, Boca Raton, 163.
|
[13]
|
O’Rielly, D.R., Miller, L.K. and Luckow, V.A. (1992) Baculovirus expression vectors, a laboratory Manuual [M]. Freeman, New York.
|
[14]
|
Astrup, T. and Mullertz, S. (1952) The fibrin plate method for estimating fibrinolytic activity. Archives of Biochemistry and Biophysics, 40, 346-351.
doi:10.1016/0003-9861(52)90121-5
|
[15]
|
Bradford, M.M. (1976) A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye-binding. Analytical Biochemistry, 72, 248-54. doi:10.1016/0003-2697(76)90527-3
|
[16]
|
Bode, C., Nordt, T.K. and Runge, M.S. (1994) Thrombolytic therapy in myocardial infarction. Annals of Hematology, 69, 35-40. doi:10.1007/BF02215957
|
[17]
|
Rapaport, E. (1991) Thrombolysis, anticoagulation, and reocclusion. American Journal of Cardiology, 68, 17E22E. doi:10.1016/0002-9149(91)90301-Z
|
[18]
|
Eisenberg, P.R. (1993) Mechanisms of reocclusion after coronary thrombolysis. Zeitschrift für Kardiologie, 82, Suppl. 2, 175-178.
|
[19]
|
Dennis, M.S., Henzel, W.J., Pitti, R.M., Lipari, M.T., Napier, M.A., Deisher, T., Bunting, S. and Lazarus, R.A. (1989) Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: Evidence for a family of platelet-aggregation inhibitors. Proceedings of the National Academy of Sciences, 87, 2471-2475.
doi:10.1073/pnas.87.7.2471
|
[20]
|
Shebuski, R.J., Stabilito, I.J., Sitko, G.R. and Polokoff, M.H. (1990) Acceleration of recombinant tissue-type plasminogen activator induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis. Circulation, 82, 169-177. doi:10.1161/01.CIR.82.1.169
|
[21]
|
Shebuski, R.J., Berry, D.E., Bennett, D.B., Storer, B.L., Ali, F. and Samanen, J. (1989) Demonstration of Ac-ArgGly-Asp-Ser-NH2 as an antiaggregatory agent in the dog intracoronary administration. Thrombos Haemostas, 61, 183-188.
|